Contraceptive efficacy of once-weekly oral administration of 2.5 mg R 2323
| Autor: | E. Sakiz, T. Ojasoo, G. Azadian-Boulanger, F. Laraque |
|---|---|
| Rok vydání: | 1976 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Population Administration Oral Physiology Endometrium Chlormadinone acetate chemistry.chemical_compound Pregnancy Oral administration Norgestrienone Norgestrel medicine Humans education Menstruation Disturbances Gynecology education.field_of_study business.industry Obstetrics and Gynecology Metrorrhagia Contraception Clinical research Norpregnatrienes Reproductive Medicine chemistry Delayed-Action Preparations Megestrol acetate Drug Evaluation Female medicine.symptom business Progestin medicine.drug |
| Zdroj: | Contraception. 14:275-284 |
| ISSN: | 0010-7824 |
| DOI: | 10.1016/0010-7824(76)90094-9 |
| Popis: | In a clinical trial involving once-weekly oral administration of 2.5 mg of R 2323 (13-ethyl-17-hydroxy-18, 19-dinor-17α-pregna-4, 9, 11-trien-20-yn-3-one) to 181 women over 2971 months of use, a drug-failure rate of 4.4% and a patient failure rate of 2.8% were recorded. No side effects, other than slight menstrual disturbances, were observed. The mechanisms underlying the efficacy of treatment with this compound, known for its weak progestin and marked anti-progesterone properties, are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|